Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I/IIa Trial Evaluating Safety of LOAd703, an Armed Oncolytic Adenovirus for Pancreatic Cancer

Summary

The purpose of this phase I/IIa trial is to see if LOAd703 (an oncolytic adenovirus) can be safely given to patients with pancreatic cancer. It will be given in addition to standard of care treatment with gemcitabine.

General Information

NCT#: NCT02705196
Study ID: LOKON001
Trial Phase: Phase I/II

Trial Sponsor: Lokon Pharma AB
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, LOAd703 Injection

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search